Clinical Trials for Cancer: A Complete Patient Guide

Every major cancer treatment advance of the last 30 years — checkpoint immunotherapy, targeted tyrosine kinase inhibitors, CAR-T cell therapy, CDK4/6 inhibitors, PARP inhibitors — was discovered and proven in clinical trials. For cancer patients, clinical trials are not a last resort. In many cases, they are the most direct path to the most advanced available therapy.

This guide explains how cancer clinical trials work, what types exist across the major tumor types, how biomarkers affect eligibility, and how to find trials matched to your specific cancer and treatment history.

Why Cancer Clinical Trials Matter

Oncology is the most active area in clinical research. In any given year, more than 15,000 cancer clinical trials are recruiting in the United States. The reason is simple: cancer is not one disease. Breast cancer alone has at least a dozen clinically meaningful subtypes, each with distinct biology, treatment responses, and optimal therapies. Clinical trials are the mechanism through which science identifies which treatments work for which patients — and which don't.

For patients, this matters in two ways. First, participating in a trial may give you access to a drug or combination that isn't yet FDA-approved — sometimes one that turns out to be significantly better than existing options. Second, even trials that don't produce a new drug generate evidence that guides the next generation of care for people with your diagnosis.

How Cancer Trials Are Different from Other Trials

Cancer clinical trials have several features that distinguish them from trials in other disease areas:

• Biomarker-driven eligibility. Most modern oncology trials require molecular tumor profiling — specific gene mutations, protein expression levels, or immune cell markers — to determine eligibility. A trial for a BRAF-mutated melanoma drug will only enroll patients whose tumors carry a BRAF mutation.
• Phase 1 trials often enroll patients (not healthy volunteers). Cancer drugs typically have significant toxicity, so it is unethical to test them in healthy people. Phase 1 oncology trials enroll patients with advanced cancer who have exhausted standard options.
• Prior therapy lines matter enormously. Most cancer trials specify how many prior lines of treatment you must have received — "≥1 prior platinum-based therapy" or "≥2 prior lines including an anti-PD-1" are typical eligibility requirements.
• Performance status is a near-universal criterion. Oncology trials almost always require a minimum ECOG performance status (0–1, meaning fully active or able to do light activity) or Karnofsky score. Patients with poor functional status are generally ineligible due to safety concerns.
• Basket and umbrella trials. Modern oncology increasingly uses biomarker-first designs — a trial may enroll multiple tumor types that share a molecular target (basket) or test multiple drugs within a single tumor type (umbrella).

Types of Cancer Clinical Trials

Treatment trials

The most common type — testing new drugs, biologics, combinations, or procedures. Treatment trials span all disease stages:

• First-line (frontline) trials: Test a new drug as initial therapy for newly diagnosed patients who have received no prior treatment.
• Adjuvant trials: Test drug treatment after surgery or radiation to prevent recurrence in early-stage disease.
• Neoadjuvant trials: Test treatment before surgery to shrink tumors and assess biological response.
• Second-line and beyond: Test options for patients who relapsed or progressed after first-line treatment.
• Maintenance trials: Test whether continuing a therapy after initial response prolongs remission.

Immunotherapy trials

Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4), CAR-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, bispecific T-cell engagers, cancer vaccines, and combinations of these approaches represent the most active area in oncology clinical development.

Targeted therapy trials

Drugs that target specific molecular alterations: EGFR inhibitors for EGFR-mutated lung cancer, HER2-targeted agents for HER2-amplified breast and gastric cancer, BRAF/MEK inhibitors for BRAF V600-mutated melanoma, KRAS G12C inhibitors, PARP inhibitors for BRCA-mutated cancers, and dozens of other targets.

Antibody-drug conjugate (ADC) trials

ADCs combine a monoclonal antibody targeting a tumor surface protein with a cytotoxic payload. Recent approvals of trastuzumab deruxtecan, sacituzumab govitecan, and enfortumab vedotin have made this one of the hottest areas in oncology. Many ADC trials test in tumor types beyond the first approval.

Prevention trials

Test interventions in people at high risk of developing cancer but who do not yet have it — such as chemoprevention trials for BRCA carriers or individuals with high-risk colon polyps.

Observational and biomarker studies

Natural history studies, tumor registry studies, and biomarker validation trials collect data and tissue samples without testing a specific treatment. These studies are lower risk and help build the evidence base that guides future trial design.

How Biomarkers Shape Cancer Trial Eligibility

Modern oncology is fundamentally biomarker-driven. Before you can evaluate whether a trial might be relevant to you, you need to know your tumor's molecular profile.

Trials by Major Cancer Type

How Trial Phases Work in Oncology

The phases of oncology clinical trials follow the standard framework (Phase 1 safety → Phase 2 efficacy → Phase 3 confirmation → Phase 4 surveillance) but with oncology-specific features:

Phase 1 in oncology: dose escalation

Oncology Phase 1 trials use a 3+3 dose escalation design or more modern BOIN/mTPI designs: cohorts of 3–6 patients receive escalating doses of the drug, with safety monitoring between each level. The goal is identifying the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Most Phase 1 oncology trials now also include dose expansion cohorts — larger groups of biomarker-selected patients who receive the RP2D to generate preliminary efficacy data.

Phase 2: proof of concept in defined populations

Oncology Phase 2 trials are increasingly biomarker-selected and use objective response rate (ORR) or progression-free survival (PFS) as the primary endpoint. These endpoints can be assessed faster than overall survival (OS), accelerating the development timeline. A strong Phase 2 ORR in a biomarker-defined population often supports FDA Accelerated Approval while a Phase 3 confirmatory trial is ongoing.

Phase 3: registrational trials

Oncology Phase 3 trials are typically randomized, controlled, and adequately powered to demonstrate a statistically significant improvement in a clinically meaningful endpoint — most commonly PFS or OS. These are the studies that generate the evidence for full FDA approval and label inclusion as a treatment option. Phase 3 trials often have more sites, broader eligibility criteria (more accessible), and more community hospital involvement than Phase 1 or 2.

Understanding the Control Arm in Cancer Trials

One of the most common concerns patients have is "What if I get the placebo?" In oncology, pure placebo control is rarely used when an effective treatment exists. The control arm in most cancer trials is one of the following:

Before enrolling, always ask your oncologist and the research coordinator: "What is the control arm in this trial, and what treatment would I receive if I'm randomized there?"

Finding a Cancer Clinical Trial

Start with your molecular profile

Before searching, gather your tumor's molecular information from your oncologist: NGS panel results, IHC staining results (PD-L1, HER2, MMR proteins), and any germline test results (BRCA, Lynch syndrome). This information maps directly to biomarker-required trial eligibility.

Search by condition on Tidera Health

Tidera searches ClinicalTrials.gov in real time and explains trial eligibility in plain English — including what biomarkers are required and what prior treatment criteria apply. Search your specific cancer type (e.g., "triple negative breast cancer" or "NSCLC EGFR mutation") to see trials matched to your profile.

Search NCI's clinical trials database

The National Cancer Institute maintains its own curated trial finder at cancer.gov/about-cancer/treatment/clinical-trials. It allows filtering by cancer type, phase, location, and trial type and lists trials at NCI-designated cancer centers.

Ask about trials at NCI-designated cancer centers

The NCI designates 71 cancer centers across the United States as centers of excellence in cancer research. These institutions run the most Phase 1 and 2 trials and have dedicated research coordinators and patient navigators for trial enrollment. If you're not already being seen at one, a second opinion visit is often worthwhile.

What to Ask Your Oncologist

These questions are specific to oncology and will help you assess whether a cancer trial is right for your situation:

• "Have I had comprehensive NGS testing? If not, am I a candidate for it?"
• "Based on my molecular profile, am I eligible for any biomarker-matched trials?"
• "What is my ECOG performance status and does it meet trial eligibility thresholds?"
• "How many prior lines of therapy have I had, and does that affect my eligibility for trials?"
• "Are there Phase 1 trials at your institution or at an NCI center I should know about?"
• "What is the control arm in the trial you're recommending — and what do I receive if randomized there?"
• "If I join this trial and come off study, what are my options next?"
• "Is there an open-label extension after the randomized period?"
• "Would this trial allow me to continue some of my current supportive care medications?"
• "What would you do if this were you or a family member in my situation?"

Frequently Asked Questions

Can I join a cancer trial while currently receiving chemotherapy?

It depends entirely on the specific trial. Some trials allow enrollment on stable background therapy; most require a washout period from prior chemotherapy (typically 3–4 weeks or the last dose plus adequate recovery). First-line trials require no prior systemic therapy. Always ask the research coordinator about washout requirements for your current regimen.

What is "treatment-naive" in oncology trial eligibility?

Treatment-naive (or "first-line eligible") means you have received no prior systemic therapy for your current cancer diagnosis. Many first-line trials specifically require this. If you received neo-adjuvant or adjuvant chemotherapy and later relapsed, you are generally not considered treatment-naive for the metastatic setting.

Does being in a clinical trial affect my insurance coverage?

The Affordable Care Act requires most health insurance plans to cover routine care costs for patients enrolled in clinical trials. The trial sponsor covers the investigational drug and study-specific procedures. However, coverage rules vary by plan, state, and whether the trial is federally funded. Before enrolling, ask both the research coordinator and your insurer about coverage specifics.

What happens to my care if the trial drug stops working?

You come off the study and return to standard care. Your oncologist will discuss next treatment options. Coming off a trial is not considered a failure — it's information. Trial protocols specify what happens at disease progression, and the research team works with your oncologist to transition you appropriately.

Can I be in two clinical trials at the same time?

Almost never. Virtually all clinical trials explicitly exclude patients currently enrolled in another interventional trial. The exception is observational studies, which typically allow concurrent enrollment in treatment trials.

What is a "basket trial" and am I a candidate?

A basket trial enrolls patients across multiple tumor types based on a shared molecular alteration — for example, a trial for any solid tumor with an NTRK fusion, regardless of tumor origin. If your NGS panel reveals a targetable alteration that appears in a basket trial, you may be eligible even if your tumor type isn't one that's typically targeted by that drug. Ask your oncologist specifically: "Based on my NGS results, am I eligible for any tumor-agnostic or basket trial?"

Explore by Specific Cancer Type